生物活性

• 描述CX-157 is a reversible inhibitor of monoamine oxidase-A (MAO-A) with an EC50 of 19.3 ng/mL.
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT00739908	Major Depressive Disorder	Phase 2	Completed	-	United States, Alabama ... more >> Birmingham Research Group Birmingham, Alabama, United States, 35216 United States, California Southwestern Research, Inc. Beverly Hills, California, United States United States, District of Columbia The George Washington University Washington, District of Columbia, United States United States, Florida Irving S. Kolin, M.D. Winter Park, Florida, United States, 32789 United States, Illinois Midwest Center for Neurobehavioral Medicine Oakbrook Terrace, Illinois, United States United States, Maryland Capital Clinical Research Associates Rockville, Maryland, United States United States, Massachusetts McLean Hospital Belmont, Massachusetts, United States United States, New Jersey CRI Worldwide, LLC Clementon, New Jersey, United States United States, New York Fieve Clinical Services New York, New York, United States United States, North Carolina Richard H. Weisler, M.D., P.A. Raleigh, North Carolina, United States United States, Pennsylvania University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, United States United States, Texas FutureSearch Trials Austin, Texas, United States, 78756 United States, Washington Summit Research Network (Seattle), LLC Seattle, Washington, United States United States, Wisconsin Northbrooke Research Center Brown Deer, Wisconsin, United States Collapse <<
  NCT01246908	Treatment Resistant Depression	Phase 2	Completed	-	-
  NCT01633437	Major Depressive Disorder	Phase 1	Completed	-	United States, Florida ... more >> Comprehensive Phase One Miramar, Florida, United States, 33025 Collapse <<

• 更多